SS-31 Research Overview

Compound Overview

SS-31 (D-Arg-Dmt-Lys-Phe-NH₂) belongs to a class of Szeto-Schiller (SS) peptides developed by Hazel Szeto and Peter Schiller at Weill Cornell Medical College. The compound's distinctive alternating aromatic-cationic structure enables its spontaneous accumulation at the inner mitochondrial membrane (IMM) — a property driven by the large negative membrane potential (ΔΨm, approximately −180 mV) across the IMM. This selective mitochondrial targeting without requiring a carrier or conjugation to a lipophilic cation is a defining pharmacological feature of the SS peptide class.

SS-31 has undergone the most extensive clinical development of any SS peptide, advancing through Phase II/III trials under the name Elamipretide (Stealth BioTherapeutics) for conditions including Barth syndrome, heart failure with reduced ejection fraction (HFrEF), and primary mitochondrial myopathy. While late-stage trials produced mixed results, the mechanistic and preclinical evidence base is substantial.

Mechanism of Action

SS-31's primary molecular target is cardiolipin — a unique phospholipid found almost exclusively in the IMM, where it constitutes approximately 20% of total lipid content. Cardiolipin plays essential structural roles in organizing the electron transport chain (ETC) supercomplexes (respirasomes) and maintaining the cristae architecture necessary for efficient oxidative phosphorylation (OXPHOS).

Under conditions of oxidative or ischemic stress, cardiolipin undergoes peroxidation and structural disruption, causing ETC supercomplex dissociation, reduced ATP synthesis, increased electron leak (generating superoxide), and release of cytochrome c — a key initiator of intrinsic apoptosis. SS-31 binds cardiolipin via electrostatic and hydrophobic interactions, stabilizing cardiolipin structure and protecting it from peroxidative damage.

Downstream Bioenergetic Effects

By preserving cardiolipin integrity, SS-31 maintains ETC complex I–IV organization and activity. Research consistently shows that SS-31 treatment in mitochondrial dysfunction models: (1) increases ATP production rate, (2) reduces mitochondrial ROS generation, (3) normalizes mitochondrial membrane potential, and (4) prevents cristae remodeling and cytochrome c release. These effects collectively improve cellular bioenergetics in metabolically stressed tissues.

Cardioprotection Research

The most robust preclinical evidence for SS-31 concerns cardiac ischemia-reperfusion (I/R) injury — the cellular damage occurring when blood flow is restored after ischemia (as in myocardial infarction treated with reperfusion therapy). In rodent I/R models, SS-31 administered before or at the onset of reperfusion consistently reduces infarct size by 40–60% compared to controls, with corresponding improvements in cardiac function (ejection fraction, stroke volume) and reductions in apoptotic cardiomyocyte markers.

The mechanistic interpretation is that reperfusion-induced oxidative burst peroxidizes cardiolipin, triggering the mitochondrial permeability transition pore (mPTP) and cytochrome c release. SS-31's cardiolipin stabilization attenuates this cascade, preserving cardiomyocyte viability during the reperfusion injury window.

In the clinical setting, the EMBRACE STEMI trial (Phase II) studied IV SS-31 in anterior STEMI patients undergoing primary PCI. While the trial showed trends toward infarct size reduction and preserved ejection fraction at 30 days, the results did not reach statistical significance, highlighting the challenges of translating robust preclinical cardioprotection to clinical endpoints.

Renal Research

The kidney is among the most metabolically active organs, with proximal tubular cells nearly entirely reliant on OXPHOS for energy. This mitochondrial dependence makes renal tissue particularly vulnerable to mitochondrial dysfunction. SS-31 has been studied in models of acute kidney injury (AKI) from ischemia, cisplatin nephrotoxicity, and contrast-induced nephropathy — all conditions in which mitochondrial dysfunction plays a central mechanistic role.

In cisplatin AKI mouse models, SS-31 pretreatment significantly preserved renal tubular architecture, reduced BUN and creatinine elevation, and decreased tubular apoptosis. Similar findings have been reported in renal ischemia-reperfusion models, with SS-31 reducing proximal tubular mitochondrial fragmentation and restoring OXPHOS capacity.

Aging and Skeletal Muscle Research

Mitochondrial dysfunction is considered a hallmark of skeletal muscle aging (sarcopenia). Research in aged rodents has shown that SS-31 treatment improves ex vivo mitochondrial respiration, increases in vivo muscle fatigue resistance, and restores age-related declines in muscle contractile force. A particularly notable study by Siegel et al. (2013) showed that a single systemic dose of SS-31 in old mice restored isolated mitochondrial respiration to levels comparable to young controls within hours — suggesting a rapid, direct bioenergetic rescue rather than a slow adaptive response.

Unlike many antioxidants that scavenge ROS non-selectively, SS-31 does not act as a direct free radical scavenger. Its antioxidant effect is mechanistic: by preventing cardiolipin peroxidation and maintaining ETC integrity, it reduces the rate of electron leak that generates mitochondrial superoxide in the first place. This upstream mechanism may explain its efficacy at concentrations where conventional antioxidants are insufficient.

Primary Mitochondrial Disease Research

Elamipretide (SS-31) has been studied in primary mitochondrial myopathy (PMM) — a group of genetic disorders caused by mutations in mitochondrial or nuclear genes encoding ETC components. In the MMPOWER-3 Phase III trial, daily subcutaneous elamipretide was evaluated in PMM patients over 24 weeks. The primary endpoint (6-minute walk distance) was not met, though exploratory analyses suggested meaningful improvements in fatigue and patient-reported outcomes in specific subgroups. The trial remains the most rigorous clinical dataset available for any SS peptide.

References

1. Szeto HH. "First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics." *Br J Pharmacol*. 2014;171(8):2029–2050.
2. Birk AV, et al. "The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin." *J Am Soc Nephrol*. 2013;24(8):1250–1261.
3. Siegel MP, et al. "Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice." *Aging Cell*. 2013;12(5):763–771.
4. Gibson CM, et al. "EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury." *Eur Heart J*. 2016;37(16):1296–1303.
5. Karaa A, et al. "Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy." *Neurology*. 2018;90(14):e1212–e1221.